Stocks and Investing
Stocks and Investing
Fri, February 8, 2013
[ 07:45 AM ] - United States, WOPRAI
[ 04:48 AM ] - United States, WOPRAI
[ 04:48 AM ] - United States, WOPRAI
[ 04:47 AM ] - United States, WOPRAI
[ 04:47 AM ] - United States, WOPRAI
[ 04:47 AM ] - United States, WOPRAI
[ 04:46 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 03:47 AM ] - United States, WOPRAI
[ 03:46 AM ] - United States, WOPRAI
[ 03:46 AM ] - United States, WOPRAI
[ 03:46 AM ] - United States, WOPRAI
[ 03:45 AM ] - United States, WOPRAI
[ 01:06 AM ] - United States, Market Wire
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $185 on, Feb 8th, 2013
Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $175 to $185 on, Feb 8th, 2013.
Evan has made no other calls on BIIB in the last 4 months.
There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 3 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
- Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Decreased Target to $139 on, Thursday, January 3rd, 2013
This is the rating of the analyst that currently disagrees with Evan
- Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013
Contributing Sources